Simplyali241

VIMTA Labs LONG after multiyear breakout

做多
NSE:VIMTALABS   VIMTA LABORATORIES
Vimta Labs is engaged in the business of testing food and drugs. It also does contract research for clinical research and pre-clinical studies.
Company was expected to give good quarter and has delivered.

VIMTA LABS: Q2 CONS NET PROFIT 97M RUPEES VS 75M (YOY); 81M (QOQ) || Q2 REVENUE 754M RUPEES VS 593M (YOY); 613M (QOQ)
DII have bought significantly in the last quarter, Some news is coming up
TARGET : See CHART

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。